Platelets have more than one binding site for von Willebrand factor

Area of Science:

• Hematology
• Molecular Biology
• Biochemistry

Background:

• Von Willebrand factor (vWF) mediates platelet adhesion and aggregation, crucial processes in hemostasis.
• Platelet activation by agonists like thrombin and ADP can lead to vWF binding, but the precise mechanisms are not fully elucidated.

Purpose of the Study:

• To investigate the distinct mechanisms and binding sites involved in von Willebrand factor (vWF) interaction with activated platelets.
• To differentiate the roles of platelet glycoproteins (GPs) in vWF binding under various activation conditions.

Main Methods:

• Utilized radiolabeled 125I-von Willebrand factor (125I-vWF) binding assays with human platelets.
• Employed monoclonal antibodies targeting platelet membrane glycoproteins (GPIb and GPIIb/IIIa) to block specific interactions.
• Studied vWF binding in response to different agonists: thrombin, ADP, ADP + epinephrine (EPI), and ristocetin.
• Examined vWF binding in platelets from patients with Bernard-Soulier syndrome (lacking GPIb).

Main Results:

• Platelet activation by thrombin, ADP, and ADP + EPI induces specific, saturable, and reversible 125I-vWF binding requiring active metabolism and divalent cations.
• Ristocetin-induced binding is independent of active metabolism and divalent cations, suggesting a different mechanism.
• Monoclonal antibodies against GPIb blocked ristocetin-induced binding but not thrombin- or ADP + EPI-induced binding.
• Platelets lacking GPIb showed increased thrombin-induced vWF binding.
• Monoclonal antibodies against GPIIb/IIIa blocked thrombin- and ADP + EPI-induced binding but not ristocetin-induced binding.
• A control IgG antibody confirmed Fc receptor independence.

Conclusions:

• Platelets possess multiple binding sites for von Willebrand factor (vWF).
• Different platelet activation stimuli expose distinct vWF binding sites and involve different molecular mechanisms.
• The GPIb-GPV complex and the GPIIb/IIIa complex mediate vWF binding through separate pathways depending on the agonist.